Nasopharyngeal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

NPC is clinically staged according to the International Union Against Cancer (UICC) and American Joint Committee on Cancer (AJCC) staging system (Table 1). Routine staging procedures include history, physical examination including cranial nerve examination, complete blood cell count, serum biochemistry (including liver function test), chest X-ray, nasopharyngoscopy, computed tomography (CT) scan or magnetic resonance imaging (MRI) of nasopharynx and base of skull and neck. MRI is preferred if available [III, B]. Imaging for distant metastases including isotope bone scan and CT scan of chest and upper abdomen could be considered for at-risk subsets (node positive, especially N3 stage) and for those patients with clinical or biochemical abnormalities detected [III, B]. The use of positron emission tomography is under investigation and findings seem promising. Both the pre-treatment and post-treatment plasma/serum load of Epstein–Barr viral DNA has been shown to be of prognostic value [III, B].

[1]  S. Leung,et al.  Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Leung,et al.  Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Pignon,et al.  Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. , 2006, International journal of radiation oncology, biology, physics.

[4]  B. O'Sullivan,et al.  Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Machin,et al.  Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Mok,et al.  Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. , 2005, Journal of the National Cancer Institute.

[7]  Jun Ma,et al.  Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Chan,et al.  Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma , 2005, Cancer.

[9]  J. Sham,et al.  Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Chen-Yi Hsu,et al.  Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Leung,et al.  Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. , 2002, Journal of the National Cancer Institute.

[12]  S. Leung,et al.  Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. , 1999, Cancer research.

[13]  M. Leblanc,et al.  Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Sobin,et al.  The world health organization histological classification of tumours of the upper respiratory tract and ear. A commentary on the second edition , 1993, Cancer.